

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-03)

ETESEVIMAB

PRONUNCIATION

e" te sev' i mab

THERAPEUTIC CLAIM

Treatment of SARS-CoV-2 Infection (COVID-19)

## CHEMICAL NAMES

1. Immunoglobulin G1 [236-alanine,237-alanine], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein) (human monoclonal LY3832479  $\gamma$ 1-chain), disulfide with human monoclonal LY3832479  $\kappa$ -chain, dimer (CAS)
2. Immunoglobulin G1\*03-kappa, anti-(*Severe acute respiratory syndrome coronavirus 2* Spike glycoprotein (Peplomer protein, E2)); human monoclonal antibody;  $\gamma$ 1 heavy chain (1-449) [*Homo sapiens* VH (IGHV3-66\*01 (97%) – (IGHD)-IGHJ4\*01 (93%)) [8.7.13] (1-119) -*Homo sapiens* IGHG1\*03 {CH<sub>2</sub>[L<sup>4</sup>>A(236),L<sup>5</sup>>A(237)]} (120-449)] (222-216')-disulfide with  $\kappa$  light chain (1'-216') [*Homo sapiens* V-KAPPA (IGKV1-39\*01 (98%) –IGKJ2\*01)[6.3.11] (1'-109') -*Homo sapiens* IGKC\*01 (110'-216')], dimer (228-228":231-231")-bisdisulfide (IUPAC)
3. Immunoglobulin G1 [236-alanine,237-alanine], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor-binding domain) (human monoclonal JS016  $\gamma$ 1-chain), disulfide with human monoclonal JS016  $\kappa$ -chain, dimer

## STRUCTURAL FORMULA

### Heavy chain X & X''

EVQLVESGGG	LVQPFGSLRL	SCAASGFTVS	SNYMSWVRQA	PGKGLEWVSV	50
IYSGGSTFYA	DSVKGRFTIS	RDNSMNTLFL	QMNSLRAEDT	AVYYCARVLP	100
MYGDYLDYWG	QGTLVTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150
YFPEPVTVSW	NSGALTSGVH	TFPAVLQSSG	LYSLSSVTV	PSSSLGTQTY	200
ICNVNHKPSN	TKVDRKVEPK	SCDKTHTCPP	CPAPEAAGGP	SVFLFPPKPK	250
DTLMISRTP	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS	300
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350
YTLPPSREEM	TKNQVSLTCL	VKGFYPSDIA	VEWESNGQPE	NNYKTTTPVL	400
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK	449

### Light chain X' & X'''

DIVMTQSPSS	LSASVGDRTV	ITCRASQSI	RYLNWYQQK	GKAPKLLIYA	50'
ASSLQSGVPS	RFSGSGSGTD	FTLTISLQ	EDFATYYCQ	SYSTPPEYTF	100'
GQGTLKLEIKR	TVAAPSVFIF	PPSDEQLKSG	TASVCLLN	FYPREAKVQW	150'
KVDNALQSGN	SQESVTEQDS	KDSTYLSST	LTLSKADYK	HKVYACEVTH	200'
QGLSSPVTKS	FNRGEC				216'

### Disulfide bridges location

22-95	22"-95"	23'-88'	23'''-88'''	136'-196'	136'''-196'''	146-202	146"-202"
222-216'	222"-216'"	228-228"	231-231"	263-323	263"-323"	369-427	369"-427"

### Glycosylation sites (N)

Asn-299 Asn-299"

## MOLECULAR FORMULA

C<sub>6436</sub>H<sub>9958</sub>N<sub>1710</sub>O<sub>2022</sub>S<sub>48</sub> . (non glycosylated)

MOLECULAR WEIGHT	145.18 kDa
TRADEMARK	None as yet
SPONSOR	Eli Lilly & Co.
CODE DESIGNATIONS	LY3832479, JS016, CB6, NP005
<u>CAS</u> REGISTRY NUMBER	2423948-94-9
UNII	N7Q9NLF11I
WHO NUMBER	11873

gbk